Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing dendritic cell-based immunotherapy in multiple myeloma.

Qing Yi1, Raman Desikan, Bart Barlogie

  • 1Myeloma and Transplantation Research Center, University of Arkansas for Medical Science, 4301 West Markham Street, Little Rock, AR 72205, USA. YiQing@uams.edu

British Journal of Haematology
|April 26, 2002
PubMed
Summary

Subcutaneous vaccination with mature dendritic cells (DCs) pulsed with idiotype protein shows promise for multiple myeloma. This approach successfully induced specific T-cell and B-cell responses, leading to stable disease in most patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

Blood cancer journal·2026
Same author

Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma.

Haematologica·2026
Same author

Distinct populations of vascular smooth muscle and sinoatrial progenitors are localized adjacent to pro-epicardium.

Cell reports·2025
Same author

Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma.

British journal of haematology·2025
Same author

Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging.

Blood advances·2025
Same author

Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice.

Haematologica·2025

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • Previous dendritic cell (DC) vaccination attempts for multiple myeloma yielded poor results due to immature DCs and suboptimal administration routes.
  • Immature DCs are less effective in T-cell activation and can lose potency.
  • Intravenous DC administration leads to sequestration in lungs and liver, hindering lymphoid organ migration.

Purpose of the Study:

  • To enhance the efficacy of DC vaccination in multiple myeloma by using mature DCs administered subcutaneously.
  • To evaluate the immunogenicity and clinical outcomes of this improved DC vaccination strategy.

Main Methods:

  • Five patients with stable partial remission of multiple myeloma received subcutaneous injections of idiotype-pulsed mature DCs three times at 2-week intervals.

Related Experiment Videos

  • Immune responses were assessed using enzyme-linked immunospot (ELISPOT) and proliferation assays for T-cells, and by detecting anti-idiotypic B-cell responses.
  • Clinical outcomes and M-component levels were monitored.

    • Main Results:

    • Idiotype-specific T-cell responses were observed in four out of five patients, and B-cell responses in all five.
    • Activated T cells exhibited a type-1 cytokine secretion profile, indicating a robust immune response.
    • One patient achieved a 50% reduction in serum M-component, sustained for 6 months; three patients had stable disease for 6 months.
    • The patient who did not mount an immune response relapsed.

    Conclusions:

    • Subcutaneous administration of mature, idiotype-pulsed DCs is immunogenic in multiple myeloma patients.
    • This strategy induces specific T- and B-cell responses and shows potential for clinical benefit.
    • Further optimization of DC generation, administration, and in vitro assays for monitoring T-cell cytotoxicity is ongoing.